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Background: Respiratory syncytial virus (RSV) infection is a common cause of pediatric hospitalization. microRNA,
key regulators of the immune system, have not previously been investigated in respiratory specimens during viral
infection. We investigated microRNA expression in the nasal mucosa of 42 RSV-positive infants, also comparing
microRNA expression between disease severity subgroups.
Methods: Nasal mucosa cytology specimens were collected from RSV-positive infants and healthy controls. 32
microRNA were selected by microarray for qPCR verification in 19 control, 16 mild, 7 moderate and 19 severe
disease samples.
Results: Compared to healthy controls, RSV-positive infants downregulated miR-34b, miR-34c, miR-125b, miR-29c,
mir125a, miR-429 and miR-27b and upregulated miR-155, miR-31, miR-203a, miR-16 and let-7d. On disease subgroups
analysis, miR-125a and miR-429 were downregulated in mild disease (p = 0.03 and 0.02, respectively), but not in severe
disease (p = 0.3 and 0.3).
Conclusion: microRNA expression in nasal epithelium cytology brushings of RSV-positive infants shows a distinct
profile of immune-associated miRNA. miR-125a has important functions within NF-κB signaling and macrophage
function. The lack of downregulation of miR-125a and miR-429 in severe disease may help explain differences in
disease manifestations on infection with RSV.
Keywords: Respiratory syncytial virus, MicroRNA, miR-34, miR-125, miR-429, miR-155, Bronchiolitis, Children,
Pediatric, Nasal mucosaBackground
Respiratory syncytial virus (RSV) infection occurs in the
majority of children during infancy [1]. Most children
have mild upper respiratory symptoms such as coryza
and cough. However, 2–3% of infants with RSV infection
are admitted to hospital, presenting clinically with bron-
chiolitis or pneumonia [2]. Efforts to develop an effective
vaccine have led to extensive investigation of the im-
mune response to RSV. Patient-based immunological in-
vestigations in RSV disease commonly use the nasal
mucosa as a proxy for the lower respiratory tract since
the lower airways are rarely available for research pur-
poses, and because limiting investigations only to inten-
sive care patients may result in selection bias. RSV* Correspondence: christopher.inchley@medisin.uio.no
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unless otherwise stated.preferentially infects epithelial cells of the respiratory
mucosa, initiating an innate immune reaction with infil-
tration of granulocytes and other myeloid cells, produc-
tion of a range of cytokines and activation of dendritic
cells [3].
microRNAs (miRNAs) are non-coding small RNA se-
quences that inhibit translation of messenger RNA
(mRNA) to protein by binding to specific target mRNA
[4]. Studies in recent years have demonstrated their role
in the regulation of multiple biological pathways within
the innate and adaptive immune systems. These path-
ways include negative feedback mechanisms to prevent
an excessive immune reaction, pathways governing cell
fate decisions and communication between innate and
adaptive immune systems [5,6]. Several studies have in-
vestigated miRNA responses to RSV in-vitro [7-9], but
to date there are no published investigations of miRNA
regulation in clinical RSV disease. We have previously. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Dicer at birth and severe infantile RSV disease [10].
Since Dicer is a key protein in miRNA biogenesis, we
considered that differential Dicer expression on infection
may result in altered miRNA profiles, which may in turn
explain why some children develop severe disease.
The aim of this investigation was two-fold: i) to de-
scribe miRNAs involved in the immune response to RSV
in a clinical setting; ii) to discover differences in miRNA
expression between disease severity groups. We have
therefore profiled miRNA in cytology brushings of the
nasal mucosa in infants with RSV disease, comparing
them to healthy infants.Methods
Patient selection
Study inclusion was during the RSV season in Akershus,
Norway, from January to March 2011. Infants < 12 months
of age examined on the pediatric emergency unit at
our hospital with an upper or lower airways infection
were considered for inclusion. A nasopharyngeal aspirate
(NPA) for virus detection and nasal mucosal cytology
specimens were taken from eligible patients on admission.
Those testing positive for RSV by either rapid antigen
testing or multiplex RT-PCR were included in the
study.Exclusion criteria
Patients born before 34 weeks gestation, with bronchopul-
monary dysplasia, chronic lung disease including treated
asthma, neurological disease, Down syndrome, hypotonia,
failure to thrive, or other specific conditions likely to con-
tribute to a more severe course of disease were excluded
from the study.Table 1 Modified respiratory distress assessment instrument
Points 0 1 2
Wheeze
Expiration None End-Expiratory 1/2
Inspiration None Partly Whole in
Location None ≤2 of 4 lung fields ≥3 of 4
Retractions
Supraclavicular No Mild Moderat
Intercostal No Mild Moderat
Subcostal No Mild Moderat
Respiratory Rate Upper limit of normal respiratory
Age < 1 month 50/ min
Age 1 – 5 months 40/ min
Age 6 – 11 months 30/ min
Note: Maximum score for wheeze - 8 points; for retractions – 9 points; for respirato
Maximum m-RDAI score is 25 points. Adapted from Lowell et al. [11]. Example - a 3
(62 – 40 = 22; 22/5 = 4.4; round up to 5).Respiratory distress
Patients were included prospectively and assessed by the
treating pediatrician for respiratory distress using a
modified Respiratory Distress Assessment Instrument
(m-RDAI), developed for this study from a validated
scoring system to allow a single measure of respiratory
rate [11]. The m-RDAI is described further in Table 1.
Disease severity
For disease severity subgroup analyses, infants were clas-
sified into mild, moderate or severe disease groups. The
severe disease group included infants requiring mechan-
ical ventilation, CPAP, supplemental oxygen or supple-
mental fluids (intravenous or nasogastric tube). Infants
who were admitted and who did not receive any of
the treatments described for severe disease were clas-
sified with mild disease if they had an m-RDAI ≤ 8
and with moderate disease if they had an m-RDAI 9 – 25.
All infants who were not admitted were classified with
mild disease, irrespective of m-RDAI score.
Control group
A control group of infants was recruited during routine
visits to family health clinics in our catchment area.
Control infants were included if they were healthy, with-
out signs of upper or lower respiratory disease.
Nasal samples for virus and miRNA analysis
NPAs were taken from both nostrils by deep nasal suction-
ing. RSV infection was confirmed using a rapid antigen test
(BinaxNOW RSV Card, Alere, Waltham, Massachusetts,
USA) and/or in-house RT-PCR. After removal of respira-
tory secretions by NPA, nasal epithelial cells were sampled
from each nostril by rotating a cytology brush (Medscand









1 point for each increment of 5 breaths/minute
above normal, max. 8 points
ry rate – 8 points. Thus RR, retractions and wheeze are equally weighted.
-month old child with a respiratory rate of 62 receives 5 points for Respiratory rate
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were immediately immersed in RNA stabilization reagent
RNAlater (Catalog Number R0901, Sigma-Aldrich, Saint
Louis, Missouri, USA). Epithelial cells were detached from
the brushes and stored at −80°C in RNAlater for miRNA
analysis.
Cytology
Cytology specimens from 7 infants with mild, and 5 infants
with severe disease were smeared onto a microscopy slide
for visual assessment of cell type.
RNA isolation
Epithelial cells stored at −80°C were pelleted before
homogenization in QIAzolLysis Reagent (Qiagen, Hilden,
Germany). The miRNeasy mini kit (Qiagen) was then used
according to the manufacturer’s instructions with
additional DNase treatment. Because of low yield in
the control samples, these were pooled into age and
gender-matched pairs during RNA isolation.
RNA quality control
We used the NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies) and Agilent 2100 Bioanalyzer
to assess RNA purity and integrity using the 260/280
ratio, the 260/230 ratio and the RNA integrity number
(RIN).
miRNA Microarray
miRNA expression profiling was performed on 48 samples
on Agilent Human miRNA Microarray Release 14.0, 8x15K
slides using Agilent’s miRNA Microarray System protocol
together with miRNA Spike-In Kit and miRNA Complete
Labeling and Hyb Kit. A single color array was used. Arrays
were scanned on Agilent G2565BA Microarray Scanner.
Data collection and quality assessment were performed
using Agilent Feature Extraction Software v8.5. Microarray
results are deposited in NCBI’s Gene Expression Omnibus
[12] with accession number GSE62306.
miRNA qPCR
miRNA differentially expressed between control and
disease groups were selected from the microarray for
qPCR verification. qPCR was done using looped miRNA-
specific RT-primers and sequence-specific TaqMan miRNA
Assays from Life Technologies (Table 2). The protocol for
creating custom RT and pre-amplification pools using
TaqMan Assays was used. RT and PreAmp were per-
formed according to protocol using 60 ng total RNA in
the RT-reaction. The PreAmp product was diluted 32,8
times and 4 μl were run in a total reaction volume of
25 μl in qPCR. The final concentration of TaqMan
MicroRNA Assay used was 1х together with 1х TaqMan
Universal Master Mix II, with UNG and nuclease-freewater. The reverse transcription (RT) pool was made
combining 10 μl of each 5хRT primer in a total volume of
1000 μl with 1хTE. 10 μl of each 20х TaqMan MicroRNA
Assay were combined in a total volume of 1000 μl with
1хTE in the pre-amplification. Samples were run in dupli-
cates on ABI PRISM 7900 HT Fast qPCR system and ana-
lyzed using ABI Prism SDS2.4 software (Life Technologies).
RNU24 was selected as a reference gene for normalization
after pre-validation for expression stability in a sub-set of
our samples. Samples were normalized and calibrated using
the ΔΔCq method.
Statistical analysis
Microarray results were analyzed using the R computing
environment [13]. The AgiMiRNA package with quantile
normalization [14] was used for pre-processing. Micro-
array performance was assessed using relative log expres-
sion and principal component analysis. The Linear models
for microarray (Limma) package with an empirical Bayes
approach [15] was used for statistical analysis. P-values
were adjusted for multiple testing using a false discovery
rate of 5%. Adjusted p-values < 0.05 were considered sta-
tistically significant.
PCR results were analyzed using IBM SPSS 20.0 software
and the R computing environment. First, RSV positive
samples were compared to controls using a multivariate
linear regression model with adjustment for the RNA
integrity number (RIN). There were no significant cor-
relations between age or gender and individual miRNA
expression or disease group. These variables were there-
fore not included in the multiple regression analysis.
Significance values were adjusted for multiple testing
using a false discovery rate of 5%.
Secondly, for each miRNA, boxplots of control and
disease subgroups were created. miRNAs that showed
visual evidence of differential expression between disease
groups were selected for analysis using one-way ANOVA
(adjusted for a false discovery rate of 5%), followed by
Dunnett’s test, comparing all disease groups to the con-
trol group.
Ethical issues
Written, informed consent was obtained from the guardians
of all infants prior to inclusion. The Regional Committee for
Medical and Health Research Ethics, South-East Norway
and the data-protection officer at Akershus University
Hospital approved the study protocol.
Results
Nasal samples were taken from 105 eligible RSV-positive
infants, including 40 with mild, 25 with moderate and
40 with severe disease. Fifty-nine control samples were
available. 61 samples had sufficient yield and RNA qual-
ity for qPCR analysis.
Table 2 miRBase IDs and mature miRNA sequences for
miRNAs included in the qPCR verification
miRBase ID Accession1 Assay2 Mature miRNA Sequence
hsa-let-7d-5p MI0000065 002283 AGAGGUAGUAGGUUGCAU
AGUU
hsa-let-7f-5p MIMAT0000067 000382 UGAGGUAGUAGAUUGUAU
AGUU
hsa-let-7g-5p MIMAT0000414 002282 UGAGGUAGUAGUUUGUAC
AGUU
hsa-let-7i-5p MIMAT0000415 002221 UGAGGUAGUAGUUUGUGC
UGUU
hsa-miR-16-5p MIMAT0000069 000391 UAGCAGCACGUAAAUAUU
GGCG
hsa-miR-19a-3p MIMAT0000073 000395 UGUGCAAAUCUAUGCAAA
ACUGA
hsa-miR-21-5p MIMAT0000076 000397 UAGCUUAUCAGACUGAUG
UUGA
hsa-miR-23b-3p MIMAT0000418 000400 AUCACAUUGCCAGGGAU
UACC
hsa-miR-26b-5p MIMAT0000083 000407 UUCAAGUAAUUCAGGAU
AGGU
hsa-miR-27b-3p MIMAT0000419 000409 UUCACAGUGGCUAAGUU
CUGC
hsa-miR-29c-3p MIMAT0000681 000587 UAGCACCAUUUGAAAUC
GGUUA
hsa-miR-30b-5p MIMAT0000420 000602 UGUAAACAUCCUACACU
CAGCU
hsa-miR-30d-5p MIMAT0000245 000420 UGUAAACAUCCCCGACU
GGAAG
hsa-miR-31-5p MIMAT0000089 002279 AGGCAAGAUGCUGGCAU
AGCU
hsa-miR-34b-5p MIMAT0000685 000427 UAGGCAGUGUCAUUAGC
UGAUUG
hsa-miR-34c-5p MIMAT0000686 000428 AGGCAGUGUAGUUAGCU
GAUUGC
hsa-miR-96-5p MIMAT0000095 000186 UUUGGCACUAGCACAUU
UUUGCU
hsa-miR-125a-5p MIMAT0000443 002198 UCCCUGAGACCCUUUAA
CCUGUGA
hsa-miR-125b-5p MIMAT0000423 000449 UCCCUGAGACCCUAACU
UGUGA
hsa-miR-130a-3p MIMAT0000425 000454 CAGUGCAAUGUUAAAA
GGGCAU
hsa-miR-146a-5p MIMAT0000449 000468 UGAGAACUGAAUUCCA
UGGGUU
hsa-miR-148a-3p MIMAT0000243 000470 UCAGUGCACUACAGAA
CUUUGU
hsa-miR-155-5p MIMAT0000646 002623 UUAAUGCUAAUCGUGA
UAGGGGU
hsa-miR-183-5p MIMAT0000261 002269 UAUGGCACUGGUAGAA
UUCACU
hsa-miR-200b-5p MIMAT0004571 002274 CAUCUUACUGGGCAGC
AUUGGA
hsa-miR-203a MI0000283 000507 GUGAAAUGUUUAGGA
CCACUAG
Table 2 miRBase IDs and mature miRNA sequences for
miRNAs included in the qPCR verification (Continued)
hsa-miR-205-5p MIMAT0000266 000509 UCCUUCAUUCCACCGG
AGUCUG
hsa-miR-223-3p MIMAT0000280 002295 UGUCAGUUUGUCAAAU
ACCCCA
hsa-miR-324-3p MIMAT0000762 002161 ACUGCCCCAGGUGCUG
CUGG
hsa-miR-331-3p MIMAT0000760 000545 GCCCCUGGGCCUAUCC
UAGAA
hsa-miR-375 MI0000783 000564 UUUGUUCGUUCGGCUC
GCGUGA
hsa-miR-429 MI0001641 001024 UAAUACUGUCUGGUAA
AACCGU
1miRBase accession number [41].
2Life Technologies’ assay ID.
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dance of squamous and ciliary epithelial cells, and gran-
ulocytes, confirming that our samples included nasal
mucosal cells, not simply mucous secretions. There were
no obvious differences between mild and severe disease.Microarray
14 severe RSV, 13 mild RSV and 13 control samples
were analyzed. Of 887 miRNA included on the micro-
array; 190 were detectable. Limma analysis of control,
mild and severe disease revealed 14 differentially expressed
miRNA. A further 12 miRNAs were differently expressed
in pairwise comparisons between groups. Results for sig-
nificantly regulated miRNA are presented in Figure 1 as a
heatmap. miRNA are classified according to the pattern of
expression. These 26 miRNA were selected for qPCR veri-
fication alongside miR-23b, miR-30b, miR-223, miR-146a,
miR-155 and miR-21, which have well described roles in
the immune system but were not differentially expressed in
the microarray.qPCR
Fourty-two RSV-positive and 19 control samples with
were analyzed by qPCR, including 16 with mild, 7 with
moderate and 19 with severe disease. Table 3 shows
clinical characteristics of these infants. In order to
increase the power of the analysis, 9 control and 20
RSV-positive samples included in the microarray were
also included in the qPCR.
Figure 2 shows the comparison of disease versus con-
trol for all 32 miRNAs analyzed by qPCR. miR-34b,
miR-34c, miR-125b, miR-29c, mir125a, miR-429 and
miR-27b were significantly downregulated. miR-155,
miR-31, miR-203a, miR-16 and let-7d were significantly
upregulated. Known immune functions of these miRNA
are summarized in Table 4.
Figure 1 miRNA Microarray of nasal mucosa brushings in infants infected with Respiratory syncytial virus, compared to healthy controls.
Note: Only miRNAs significant in the microarray (p < 0.05, adjusted for a false discovery rate of 5%) are shown. For each miRNA, results are
calibrated to the mean of the control group for that miRNA. Number of samples: Control 13, Mild RSV disease 13; Severe RSV disease 14. miRNAs
are grouped according to results of Limma analysis, as compared to the control group: Group A: Upregulation in RSV disease. Group B: Upregulation in
severe disease; downregulation in mild disease. Group C: Downregulation in mild disease; not regulated in severe disease. Group D: Downregulation
in RSV disease.
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miR-125a and mir-429 showed evidence of differential
expression between disease subgroups (Figure 3). Com-
pared to control, the mild and moderate disease sub-
groups show miR-125a downregulation, but not the
severe disease subgroup. miR-429 shows a similar pat-
tern, except that the downregulation in the moderate
group is not quite significant.
Discussion
We have profiled miRNA expression in nasal epithelial
cells of infants with acute RSV disease, compared to
healthy controls. In addition we find differential expres-
sion between mild, moderate and severe disease groups
for miR-125a and miR-429.
Bronchiolitis is a disease in which the entire respira-
tory tract is affected, with both upper and lower respira-
tory symptoms in the majority of children. Ethical
considerations limited this investigation to the nasal mu-
cosa since we were interested in infants not receiving in-
tensive care treatment. Several cell types were present in
our samples: granulocytes, squamous epithelial cells and
ciliary epithelial cells. We are therefore unable to make
direct conclusions about miRNA expression in cells of
the lower respiratory tract or individual cell types. We
do, however, consider that the nasal mucosa is a reason-
able site to examine the immunological response to RSVinfection. The nasal cavity is the primary site of RSV in-
fection, and children typically have coryza for several
days prior to lower respiratory symptoms. Differences in
the nasal mucosal immune response may increase the
risk of severe disease, for example by promoting dissem-
ination of viral particles to the lower respiratory tract, or
by increasing mucous production and inflammation.
RSV preferentially infects epithelial cells of the respira-
tory mucosa. We differentiated between disease sever-
ities in the setting of patients routinely admitted to
hospital, such that severe disease patients were largely
treated on the pediatric ward, not the intensive care unit.
Severe disease was distinguished from moderate disease
on the basis of supplemental oxygen or fluids, or use of
CPAP. It is therefore interesting that on admission, those
in the moderate disease group tended to more respira-
tory distress than those in the severe disease group, as
measured by the m-RDAI (Table 3). This is a similar pat-
tern to the PCR findings for miR-125a, and miR-429,
where there is regulation in mild or moderate disease
groups that is not present in the severe disease group.
Increased signs of respiratory effort may be a protective
factor, and infants who do not show these signs may ei-
ther be too tired to increase their work of breathing, or
may not have this capacity for other reasons - for ex-
ample the body’s drive (immunological or otherwise) to
respond to infection. Clinical findings should, however,
Table 3 Clinical characteristics of control and RSV-positive infants included in the qPCR analysis
Control Mild Moderate Severe Sig.
Number 19 16 7 19
Age - months, median (IQR) 3 (1 – 5) 4 (1 – 7) 2 (1 – 4) 2 (1 – 4) p = 0.61
Male gender, n (%) 11 (58%) 7 (44%) 6 (86%) 9 (47%) p = 0.52
Weight - g, mean (SD) 5773 (1647) 7098 (2350) 6615 (1392) 5826 (1845) p = 0.23
Duration of symptoms - days, median (IQR) 4.5 (3 – 6) 5 (4 – 5) 4 (3 – 5) p = 0.74
Admission, n (%) 2 (13%) 7 (100%) 19 (100%)
Length of stay, median (IQR) 0 (0 – 0) 3 (1 – 4) 4 (2 – 6) p = 0.35
Length of stay > 3 days, n (%) 0 (0%) 2 (29%) 10 (56%) p = 0.26
Respiratory Distress
SpO2 -% on admission, mean (SD) 98 (2.5) 98 (2.5) 93 (6) p = 0.0037
Respiratory rate /min on admission, mean (SD) 50 (14) 57 (8) 61 (13) p = 0.067
Respiratory rate score (max. 8), median (IQR) 1.5 (0 – 5) 4 (2 – 6) 4 (2 – 6) p = 0.164
Retraction score (max. 9), median (IQR) 1 (0 – 2) 5 (2 – 6) 2 (1 – 4) p = 0.0064
Wheeze score (max. 8), median (IQR) 1 (0 – 3) 4 (4 – 5) 2 (2 – 4.5) p = 0.0534
m-RDAI, median (IQR) 6 (1 – 8) 13 (9 – 16) 9 (7 – 13) p = 0.0044
p = 0.095
Treatments
Fluid supplement, n (%) 8 (42%)
Intravenous fluids, n (%) 2 (11%)
Nasogastric fluid, n (%) 7 (37%)
Oxygen supplement, n (%) 16 (84%)
CPAP, n (%) 3 (16%)
Respirator, n (%) 0
Note: There are no significant differences in age, weight or gender between control and RSV-positive groups. Duration of symptoms for disease subgroups was
similar. The severe disease group had a lower SpO2 on admission, but tended to less respiratory distress than the moderate group, as measured by the m-RDAI.
The retraction score in particular contributed to this difference. Length of hospital stay was statistically similar for moderate and severe disease groups, probably
due to loss of power when excluding samples with poor RNA quality (when including all children regardless of RNA quality, the median length of stay and IQR are
relatively unchanged, but Mann–Whitney p = 0.048, indicating a longer hospital stay for the severe disease group). The most common treatment for children with
severe disease was oxygen supplementation.
1Mann-Whitney test, comparing control group with RSV-positive group.
2Fischer’s exact test, comparing control group with RSV-positive group.
3T-test, comparing control group with RSV-positive group.
4Kruskal-Wallis test, comparing disease severity subgroups.
5Mann-Whitney test, comparing moderate and severe disease subgroups.
6Fischer’s exact test, comparing moderate and severe disease subgroups.
7One-way ANOVA, comparing disease severity subgroups.
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only measured on admission. If we had re-assessed re-
spiratory effort during the course of the admission we
may have discovered an increased score prior to oxygen
or fluid administration. In this prospective study, an ar-
bitrary m-RDAI cut-off was used to distinguish mild
from moderate disease groups in admitted patients. Only
two mild disease patients included in the final analysis
were admitted, and both of these had an m-RDAI score
of 6, largely due to tachypnea, with little wheeze and few
retractions. We therefore consider these patients to be
correctly categorized.
26 miRNAs were differentially regulated in the micro-
array. 11 of these were also differentially regulated in the
qPCR. Of the 6 miRNA not differentially regulated inthe microarray, one (miR-155) was differentially regu-
lated in the qPCR. For miRNA regulated in both micro-
array and qPCR, the pattern of regulation was similar in
the two analyses when grouping all RSV positive chil-
dren together (Figures 1 and 2). On subgroup analysis,
miRNA group C (see Figure 1) is of interest. Group C
includes miRNA downregulated in mild disease but not
in severe disease. miR-125a and miR-429 are in this
group, and qPCR subgroup analysis was consistent with
the microarray. miR-125b, miR-27b and miR-29c were
also in this group but did not show differences between
disease groups. The other 12 group C miRNA were not
differentially regulated in the qPCR. The use of clinical
samples with a high degree of biologically variation, the
fact that microarray is less precise than qPCR, the low
Figure 2 Nasal mucosal miRNA expression in infants infected with Respiratory syncytial virus, compared to healthy controls.
Note: Samples from 42 children with RSV were compared to 19 control samples using qPCR for selected miRNA. Values presented are
mean differences between disease and control groups with 95% confidence interval. *Multiple linear regression analysis with correction for
RIN. p-values are adjusted for a false discovery rate of 5%.
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number of samples in the qPCR may explain differences
between microarray and qPCR results.
The majority of miRNAs regulated in this study have doc-
umented functions within the immune system (see Table 4).
Expression levels of miR-34c, miR-34b and miR-125b were
reduced more than two-fold compared to control,
with significance levels several orders of magnitude
greater than the other regulated miRNAs, suggesting
that downregulation of these miRNAs in particular
may be important in the immune response to RSV.One report described miR-34c upregulation by adult
peripheral blood monocytes on exposure to damage-
associated molecular pattern molecules. In the same
paper miR-34c negatively regulated NF-κB signaling
by inhibition of Inhibitor of IKKγ [16]. Another study
showed miR-34c upregulation in umbilical cord blood
monocytes on exposure to the Th1 cytokine interferon-γ,
but not on exposure to lipopolysaccharide [17]. miR-125b
has been well studied, and a number of functions within
the immune system are described, including regulation of
NF-κB signaling [18,19], macrophage activation [20],
Table 4 Functions, known targets and disease associations of differentially expressed miRNA
miRNA Expression in this study Functions in the immune system† Specific targets† Disease associations
(Human studies)
Both innate and adaptive immune functions
miR-29c Downregulation Positive regulation of NFκB signaling [26] TNFAIP3 [26] Tuberculosis – upregulated [42]
Influenza→ Upregulation.†† Promotes apoptosis [43] BCL2L2 [43] Asthma – downregulated [37]
miR-31 Upregulation Proliferation of myeloid cells [33] E-selectin [44] Influenza – downregulated [35]
miR-155 Upregulation Proliferation of myeloid cells [33] SHIP1 [33] Influenza – downregulated [35]
Dendritic cell maturation [34,45] PU.1 [45], SOCS1,
CD115, KPC1 [34]
Positive regulation of TLR signaling [18] SOCS1 [18]
Required for dendritic, B and T-cell function [32]
let-7d Upregulation Promotes Th1 polarization [40] IL13 [40] Asthma – downregulated [46]
Endotoxin→ Upregulation (TLR4 dep.) †† [23]
Primarily innate immune functions
miR-16 Upregulation Negative regulation of inflammation [47] TNFα [47] Sepsis – improved survival [48]
Positive regulation of NFκB signaling [24] SMRT [24]
Negative regulation of NFκB signaling [28] IKKα [28]
Endotoxin→ Upregulation (TLR4 dep) †† [23]
miR-27b Downregulation TLR4/NFκB induced nitric oxide production [49] KSRP [49] Asthma – downregulated [37]
Endotoxin→ Upregulation (NFκB dep) †† [50]
miR-34b Downregulation Endotoxin→ Upregulation (TLR4 dep) †† [23] Asthma – downregulated [37]
miR-34c Downregulation Negative regulation of NFκB signaling; DAMPs*→
Upregulation [16]
IKKγ [16] Asthma – downregulated [37]
In cord blood monocytes: IFNγ→ Upregulation††;
Endotoxin→ no regulation†† [17]
miR-125a Downregulation Positive regulation of NFκB signaling [19] TNFAIP3 [19]
Inhibits CCL5 production [30] KLF13 [30]
Macrophage polarization [27,51]
miR-125b Downregulation Positive regulation of NFκB signaling [19] TNFAIP3 [19] CERS** – upregulated [52]
Negative regulation of NFκB signaling [18] MyD88 [18]
Activates Macrophages [20] IRF4 [20]
Modulates dendritic cell differentiation [21] PRDM1 [21]
Maintains naïve state in CD4+ T-cells [53] IFNγ, IL2RB, IL10RA,
PRDM1 [53]
Negative regulation of inflammation [22] TNFα [22]
miR-203a Upregulation Negative regulation of NFκB signaling [25] Myd88 [25] Asthma – upregulated [38]
Negative regulation of inflammation [54] TNFα, IL24 [54]
No known immune functions
miR-429 Downregulation
†: The functions described are extracted from a literature search April 2014, excluding studies of cancer. This table is not an exhaustive description of all known
functions for each miRNA. All studies were carried out in vitro in specific cell lines, and caution should be taken when extrapolating the data to other cells or
biological systems, including clinical disease. Specific miRNA functions and mRNA-target verification have in most cases been determined both by removing the
miRNA from the biological system and by stimulating the system with the miRNA. miRNA upregulation after cell stimulation has usually been verified by simple
qPCR. miRNA responses to cell stimulation have been included in the table if deemed relevant to virus infection or TLR/NFκB signaling.
††: X→ Upregulation (Y dep): indicates that in-vitro stimulation of a cell line with molecule or pathogen X causes upregulation of the miRNA, and that this is
dependent upon protein Y.
*DAMPs: Damage-associated molecular pattern molecules.
**CERS - Chronic Eosinophilic Rhinosinusitis.
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Figure 3 Nasal mucosal miRNA expression according to disease severity in infants infected with Respiratory syncytial virus.
Note: Relative quantities of 4 miRNAs assessed for differential expression between disease severity subgroups. Results are calibrated to
the mean of the control group, indicated by the dashed line at a relative quantity 100%. Plotted lines indicate the mean with 95% confidence
interval for each group. Numbers in each group: control 19; mild 16; moderate 7; severe 19. For miR-125a there is downregulation in mild and moderate
disease groups, but not in the severe group. For miR-429 there is a similar pattern, with downregulation in the mild group but not the severe
group. † One-way ANOVA, adjusted for a false discovery rate of 5%. * Dunnett’s post-hoc t-test after One-way ANOVA, in which mild, moderate and
severe disease severity subgroups are compared individually to the control group, with correction for multiple testing. Up- or downregulation is
therefore as compared to the control group.
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direct targeting of TNFα [22]. miR-34b has been less
studied in immunity, but was upregulated in mouse
lung tissue after injection of lipopolysaccharide [23].
NF-κB signaling is modulated by 7 miRNAs regulated
in our study: miR-16, miR-29c, miR-34c, miR-125a,
miR-125b, miR-155 and miR-203a [16,18,19,24-28]. NF-κB
activation following RSV-antigen binding to the pathogen
recognition receptors TLR 4 or RIG-1 is a primary stage in
the immunological response to RSV [29]. However, exces-
sive NF-κB activation may also have deleterious effects, and
negative regulation is also important. The miRNA regula-
tion pattern in this study implies both positive and negative
regulation of NF-κB, consistent with fine-tuning of the
immune response to RSV in our samples.
Factors that might cause some infants to have severe
disease whilst most infants have mild disease are poorly
understood and may aid development of preventative
measures and treatments for RSV. We therefore aimed
to identify differences in miRNA expression between
mild and severe disease. The variation in expression of
miR-125a and miR-429 according to disease severity is
particularly interesting in the context of innate immunity.
miR-125a is a positive regulator of NF-κB via negativeregulation of the inhibitory protein TNFAIP3 [27], and a
negative regulator of CCL5, an important cytokine in both
innate and adaptive immune systems [30]. miR-125a is over-
expressed in human macrophages, in an activated pheno-
type produced by NF-κB activation [27]. Downregulation of
miR-125a in children with mild and moderate disease may
thus represent reduced macrophage activation and inhibited
NF-κB signaling, which may protect against an excessive
innate immune response with a more severe disease
phenotype. miR-429 can reactivate dormant Epstein-Barr
virus in B-cells [31]. To our knowledge, other functions of
miR-429 within the immune system or in RSV disease
have not been described.
Upregulation of miR-155 is consistent with an acute in-
flammatory response. This miRNA is expressed in dendritic
cells and in T and B- lymphocytes and is necessary for their
function [32]. miR-155 is produced on TLR4 mediated
NF-κB activation and positively regulates myeloid prolif-
eration [33] and dendritic cell maturation [34], which is a
necessary step for dendritic cell migration to lymph nodes
and antigen presentation.
Several studies have examined in vitro responses to
RSV. RSV-stimulation upregulates miR-375 and let-7i in
human bronchial epithelial cells [8,9], and let-7f in a
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entially regulated in our microarray, but not in the qPCR
(FDR-adjusted p = 0.054, 0.068 and 0.17 for let-7i, miR-
375 and let-7f, respectively – see Figure 2). A number of
other miRNA identified in these studies were not regu-
lated in our microarray. It is probable that differences in
findings between our study and these in vitro studies
are due to the cell type analyzed. Our cytology speci-
mens included both nasal respiratory epithelial cells
and granulocytes, whilst the in-vitro studies included
alveolar or bronchial epithelial cell lines. In addition,
the increased biological variation inherent to our clin-
ical samples is likely to reduce the power of our study
to observe differences in expression.
To our knowledge, miRNAs have not been studied in
clinical disease with respiratory viruses other than in
blood samples of patients with influenza A [35,36]. This
is the first investigation of miRNA expression in clinical
samples from RSV-positive infants. Two clinical studies
profiled miRNA expression in bronchial epithelial brushings
from asthmatic adults [37,38]. Findings included upregula-
tion of miR-203a and downregulation of miR-27b, miR-29c,
miR-34b and miR-34c – an identical expression pattern to
the infants in our study. Early-life RSV infection is associ-
ated with later development of asthma [39], making this
finding particularly interesting. However, we also found
downregulation of let-7d, which targets asthma-associated
genes in vitro [40]. Further studies of the role of these
miRNA in RSV disease may provide information on mecha-
nisms underlying the association between infantile RSV
disease and later development of asthma.Conclusions
In summary, we have profiled miRNA expression patterns
in the nasal epithelium of infants with acute RSV disease.
We find an expression pattern consistent with modulation
of both innate and adaptive immune systems, including a
number of miRNAs involved in NF-κB regulation or asso-
ciated with asthma. miR-125a and miR-429 were regulated
in mild but not severe disease, warranting further investi-
gation of their role as a regulator of the immune response
to RSV.
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